Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Tirzepatide is dual: GLP-1 plus GIP
1998) demonstrated dose-dependent GH release (ED50 ~80 nmol/kg), no cortisol or prolactin elevation, and a 24% increase in bone growth rate (52 vs 42 m/day) in rat models
The first study (2023) evaluated 7,051 patients undergoing TKA who were prescribed semaglutide preoperatively, comparing them to a matched control group of 34,524 non-users
Are your colours warm or cold
Provider Comparisons The GLP-1 space is evolving fast
Conclusion Currently, there is a large population of NAFLD/NASH patients who require long-term treatment, yet there is only one approved drug specifically for NASH, Rezdiffra (resmetirom), indicating that the clinical need is far from being fully met
